Clinical trialNCT02119650TerminatedPhase 2Interventional

Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer

SponsorIncyte CorporationEnrollment76NSCLC (Non-small Cell Lung Carcinoma)

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study was to determine if ruxolitinib, in combination with Pemetrexed/Cisplatin and Pemetrexed Maintenance, is safe and effective in the treatment of nonsquamous non-small cell lung cancer (NSCLC) that is Stage IIIB, Stage IV, or recurrent.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Gerard T Kennealey, MD
Incyte Corporation
Study Director
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

30 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Facility name not stated
Phoenix, Arizona, United States
Facility name not stated
Fayetteville, Arkansas, United States
Facility name not stated
Fresno, California, United States
Facility name not stated
La Jolla, California, United States
Facility name not stated
San Diego, California, United States
Facility name not stated
San Francisco, California, United States
Facility name not stated
Lone Tree, Colorado, United States
Facility name not stated
Norwich, Connecticut, United States
Facility name not stated
Southington, Connecticut, United States
Facility name not stated
Augusta, Georgia, United States
Facility name not stated
Joliet, Illinois, United States
Facility name not stated
Indianapolis, Indiana, United States
Facility name not stated
Lafayette, Indiana, United States
Facility name not stated
Kansas City, Kansas, United States
Facility name not stated
Detroit, Michigan, United States
Facility name not stated
St Louis, Missouri, United States
Facility name not stated
Reno, Nevada, United States
Facility name not stated
Lebanon, New Hampshire, United States
Facility name not stated
Mount Kisco, New York, United States
Facility name not stated
New York, New York, United States
Facility name not stated
Winston-Salem, North Carolina, United States
Facility name not stated
Canton, Ohio, United States
Facility name not stated
Portland, Oregon, United States
Facility name not stated
Chattanooga, Tennessee, United States
Facility name not stated
Knoxville, Tennessee, United States
Facility name not stated
Memphis, Tennessee, United States
Facility name not stated
Ogden, Utah, United States
Facility name not stated
Leesburg, Virginia, United States
Facility name not stated
Kennewick, Washington, United States
Facility name not stated
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cisplatin →Pemetrexed →PlaceboRuxolitinib →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 11 Feb 2014
Primary completion: 11 Feb 2016
Completion: 21 Jun 2016
Last update posted: 13 Feb 2018
Registered enrollment: 76
Registry id: NCT02119650

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.